Management of Persistent Auditory Hallucinations

Assessment and Optimization

Verify medication adherence and ensure the patient has been on aripiprazole 15mg for at least 4 weeks, as this is the minimum duration to assess therapeutic response, according to The Lancet Psychiatry 1
Assess whether oxcarbazepine is clinically indicated, and consider that it may not be addressing the primary psychotic symptoms, as noted by the American Academy of Family Physicians 2
Evaluate the quetiapine 25mg dose, which is subtherapeutic for psychosis and only provides sedation, not antipsychotic effect, as reported by the American Academy of Family Physicians 2 and 3

If inadequate response persists after optimizing the current antipsychotic, switch to a different antipsychotic rather than adding another agent, as recommended by The Lancet Psychiatry 1
Consider switching to a high-potency antipsychotic monotherapy, such as amisulpride, risperidone, paliperidone, or olanzapine, as suggested by The Lancet Psychiatry 1
If choosing olanzapine, add metformin prophylactically to mitigate metabolic side effects, as recommended by The Lancet Psychiatry 1 and 4
Ensure gradual cross-titration when switching to avoid symptom exacerbation, as advised by The Lancet Psychiatry 1

If hallucinations persist after two adequate antipsychotic trials, initiate clozapine, as recommended by The Lancet Psychiatry 1
Target plasma level of at least 350 ng/mL for therapeutic effect, and may increase to 550 ng/mL if needed, as suggested by The Lancet Psychiatry 1
Co-prescribe metformin from initiation to prevent weight gain, as recommended by The Lancet Psychiatry 1 and 4

If significant hallucinations persist after 12 weeks of therapeutic clozapine levels, consider adding aripiprazole or amisulpride, as suggested by Drugs 5 and The Lancet Psychiatry 1
This combination of clozapine with a partial D2 agonist may reduce clozapine dose requirements and overall side effects, as reported by Drugs 5

Do not continue antipsychotic polypharmacy without clear benefit, as it increases side effect burden, including hyperprolactinemia, metabolic syndrome, sedation, and cognitive impairment, as noted by Drugs 6
Monotherapy should always be attempted first, and if polypharmacy is used, it should be time-limited and regularly reassessed for benefit, as recommended by Drugs 7 and The Lancet Psychiatry 1